Loading organizations...
Jung+ Longevity develops advanced, science-backed supplements to maximize healthspan, decelerate aging, and enhance vitality. Their Total Longevity System targets the twelve root causes of aging via clinically dosed, precision-timed regimens. Developed with leading experts, formulations align with key aging pathways, supported by extensive research to optimize cellular function.
Simon Sakhai founded Jung+ Longevity in Oxford, believing advanced healthy aging solutions should be widely accessible. A University of Oxford alumnus and former President of Oxford's Longevity Society, Sakhai dedicated years to studying longevity science. His background provided the insight and impetus to democratize evidence-based health optimization.
The company serves global individuals committed to enhancing health and extending vibrant years. Jung+ Longevity's mission is to liberate healthy longevity, ensuring its benefits reach "the billions, not just the billionaires." They aim to reshape conventional longevity care, providing an accessible platform for pioneering scientific advancements in human health.
Jung+ Longevity has raised $570K across 1 funding round.
Jung+ Longevity has raised $570K in total across 1 funding round.
Jung+ Longevity has raised $570K in total across 1 funding round.
Jung+ Longevity's investors include Healthspan Capital.
Jung+ Longevity has raised $570K across 1 funding round. Most recently, it raised $570K Seed in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $570K Seed | — | Healthspan Capital | Announced |
Jung+ is a consumer longevity company founded in Oxford that builds the Total Longevity System™, a precision-engineered program of supplements, lifestyle protocols, and biomarker testing to target the 12 hallmarks of aging, slow biological aging, and extend healthspan.[1][3][6] It serves everyday consumers seeking affordable access to elite longevity science—priced from around $120/month—solving the problem of high-cost clinic programs ($100,000+ annually) by offering a DTC, self-guided three-step system: a master formula (AM/PM for circadian alignment), targeted boosters (e.g., skin renewal, fasting support), and ongoing scientific updates.[1][4][5] After five years of R&D and a private beta with 10,000 users, Jung+ launched publicly in 2024, democratizing interventions like NAD+ boosting and senescent cell clearance backed by 400+ peer-reviewed studies.[1][4]
Jung+ was founded by Simon Sakhai, a University of Oxford alumnus and former President (now Chairman) of the Oxford Society of Ageing and Longevity, who assembled a team of global experts including scientists and doctors.[1][4][5] The idea emerged from Sakhai's recognition of a "17-year gap" between longevity discoveries and consumer access, inspired by elite clinics but aimed at the masses—"longevity for the billions, not just the billionaires."[1][5] Key contributors include longevity researcher Pellay, with 11+ years in skin rejuvenation and founding firms like Cell Culture Lab and Bimini Biotech.[5] After five years of R&D, pivotal early traction came via a 10,000-strong private beta community, leading to the 2024 launch of its hero products.[1][4]
Jung+ rides the consumer-driven longevity boom, where demand for anti-aging tech outpaces elite clinics, fueled by rapid science advances (medical knowledge doubling in 73 days by 2020) and consumer adoption of biomarker tracking and senolytics.[3][4][5] Timing is ideal post-2024 launch amid mainstreaming of hallmarks-of-aging research, with market forces like DTC healthtech growth and falling supplement costs enabling scalability.[1][2] It influences the ecosystem by bridging labs to consumers—updating formulas dynamically, empowering functional doctors, and proving longevity products can achieve clinic-level impact affordably, potentially accelerating mass adoption beyond billionaires.[1][4][5]
Jung+ is poised to scale via clinician partnerships and product expansions (e.g., more boosters, advanced testing), capitalizing on trends like AI-personalized longevity and mainstream NAD+ therapies.[1][3] Evolving consumer biotech will shape it—expect integrations with wearables for real-time biomarker tweaks and global trials validating outcomes. Its influence could grow by setting DTC standards, pulling more pharma into accessible healthspan tech and redefining aging as optimizable, tying back to its crusade: elite science for all.[5]
